A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

This study is currently recruiting participants.
Verified March 2014 by Sarcoma Alliance for Research through Collaboration
Sponsor:
Collaborator:
AstraZeneca
Information provided by:
Sarcoma Alliance for Research through Collaboration
ClinicalTrials.gov Identifier:
NCT00752206
First received: September 11, 2008
Last updated: March 3, 2014
Last verified: March 2014

September 11, 2008
March 3, 2014
March 2009
September 2014   (final data collection date for primary outcome measure)
To determine the progression free survival rate among patients treated with Saracatinib and placebo. [ Time Frame: Evaluation for recurrence/progression will be made every 3 months for the 1st year, then every 6 months up to 2 years, then every year up to 5 years after starting treatment. ] [ Designated as safety issue: Yes ]
To determine the progression free survival rate among patients treated with AZD0530 and placebo. [ Time Frame: Evaluation for recurrence/progression will be made every 3 months for the 1st year, then every 6 months up to 2 years, then every year up to 5 years after starting treatment. ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00752206 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung
A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Cross-over, Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, In Patients With Recurrent Osteosarcoma Localized to the Lung

The purpose of this study is to determine how long patients who undergo complete surgical removal of recurrent osteosarcoma in the lung will remain free of cancer after taking Saracatinib compared to patients taking placebo (a sugar pill).

Further details provided by SARC (Sarcoma Alliance for Research through Collaboration):

After complete surgical removal of their cancer, patients will be randomly assigned to receive either Saracatinib or placebo (a sugar pill) throughout the study. Patients will take Saracatinib (or placebo) once daily by mouth for a total of 364 days. The duration of treatment is divided into 13 cycles, 28 days each cycle with no breaks in between.

Patients will be seen for interim medical history, physical exam and laboratory studies prior to each cycle. To monitor for recurrence of tumor, patients will undergo thoracic CT scans at 3-4 weeks, 6-8 weeks, at 3 months, at 6 months, at 9 months, at 12 months, then every 6 months up to 2 years, and then every year up to 5 years after starting treatment. An electrocardiogram (ECG) will be taken at 3 months, and a bone scan will be performed at 12 months.

Patients who recur in the lung while on-study and who are thought to be amenable to complete surgical resection will be able to find out if they were receiving placebo or saracatinib. Those patients who were receiving placebo may then have the option of undergoing surgical resection. If fully resected of all recurrent disease,they will be given the option of receiving oral therapy with saracatinib. Saracatinib will be administered as a once daily, oral dose of 175 mg, for a 28-day cycle, with no breaks between cycles. The duration of treatment with saracatinib will be thirteen 28-day cycles (364 days total). If complete resection of all lung nodules is not achieved, the patient will be removed from the study.

Patients who recur in locations other than the lung while on-study will be taken off study at that time.

Blood and tumor samples for research purposes will be collected at the time the tumor is removed.

After completing all 13 cycles, patients will be followed for approximately every 3 months until 2 years from starting treatment, then approximately every 6 months until 4 years from starting treatment, and once at year 5.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Osteosarcoma
  • Drug: Saracatinib
    Oral Agent
  • Drug: Placebo
    Oral Agent
  • Active Comparator: 1
    Intervention: Drug: Saracatinib
  • Placebo Comparator: 2
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
88
September 2014
September 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient had recurrence of osteosarcoma, localized to the lungs, had complete surgical removal of all lung nodules are eligible for enrollment.
  • Patient with suspected recurrence of osteosarcoma but who has not had surgery is eligible for enrollment but will not be randomized to receive study medication until deemed fully eligible following surgical removal of all lung nodules.
  • Patient had histological confirmed diagnosis of osteosarcoma of the recurrent sample.
  • Patient had recurrence of osteosarcoma in the lung following standard therapy including: adriamycin, cisplatin, ifosfamide and methotrexate.
  • Patient is ≥ 15 and < 75 years of age.
  • Weight ≥ 34 kg.
  • ECOG performance score of 0-2.
  • Adequate bone marrow function.
  • Adequate renal function.
  • Adequate hepatic function.
  • Adequate cardiac function.
  • Women of childbearing potential must have had a negative pregnancy test (urine or serum) ≤ 7 days prior to enrollment, and willingness to use an acceptable method of contraception during participation in the study and for 3 months after the last dose.
  • Randomization must occur ≤ 6 weeks after complete surgical resection.
  • Patient or legal guardian has signed informed consent.

Exclusion Criteria:

  • Presence of metastatic disease in other locations in addition to the lung.
  • Disruption of the lung pleura by tumor.
  • Paget's disease.
  • Patient currently using, or has previously used CYP3A4 inducers or inhibitors within 2 to 14 days prior to the initiation of oral therapy.
  • Known hypersensitivity to other Src/Abl non-receptor kinase inhibitors.
  • Evidence of interstitial lung disease.
  • Any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol.
  • Myocardial infarction within one year prior to study entry.
  • Bleeding diathesis, resulting in symptomatic bleeding.
  • Patient is pregnant or nursing/breast-feeding.
  • Patient received chemotherapy, biological or investigational agent ≤ 28 days prior to enrollment.
  • Patient experiencing unresolved toxicity ≥ CTCAE grade 2 (except alopecia) from previous agents.
Both
15 Years to 74 Years
No
Contact: Denise Reinke, MS, NP, President 734-930-7600 sarc@sarctrials.org
United States
 
NCT00752206
SARC012, D8180C00039
Yes
Denise Reinke, MS, NP / President, SARC (Sarcoma Alliance for Research through Collaboration)
Sarcoma Alliance for Research through Collaboration
AstraZeneca
Principal Investigator: Kristin Baird, MD National Cancer Institute - Pediatric Oncology Branch
Sarcoma Alliance for Research through Collaboration
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP